Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
about
Multi-Institutional Competing Risks Analysis of Distant Brain Failure and Salvage Patterns after Upfront Radiosurgery without Whole Brain Radiotherapy for Brain Metastasis.Designing In and Around Tolerability Considerations for Immunotherapy Combinations.Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Control of NK Cell Activation by Immune Checkpoint Molecules.Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab.Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies.Immune Checkpoint Inhibitors in Melanoma and HIV Infection.The Most Recent Oncologic Emergency: What Emergency Physicians Need to Know About the Potential Complications of Immune Checkpoint Inhibitors.Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.B cells as biomarkers: predicting immune checkpoint therapy adverse events.Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy.Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.Immune checkpoint inhibitors: new strategies to checkmate cancer.Liquid biomarkers in melanoma: detection and discovery.The role of nivolumab in melanoma.Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.Current and future immunotherapies for thyroid cancer.Small-cell lung cancer in the era of immunotherapy.Melanoma in 2017: Moving treatments earlier to move further forwards.The Role of the Estrogen Pathway in the Tumor Microenvironment.Cancer immunotherapy: The dark side of PD-1 receptor inhibition.Impact of genomics on the surgical management of melanoma.Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations-Chances and Challenges.Treatment of uveal melanoma: where are we now?Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses.Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management.Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.Upper gastrointestinal malignancies in 2017: current perspectives and future approaches.Cutaneous melanoma: From pathogenesis to therapy (Review).When worlds collide: Th17 and Treg cells in cancer and autoimmunity.Mechanisms of Resistance to PD-1 and PD-L1 Blockade.PD-L1 expression in medulloblastoma: an evaluation by subgroup.ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.A Convergence-Based Framework for Cancer Drug Resistance.Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events.Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson.
P2860
Q46175985-73F3ADCC-1CA3-4E12-9076-AE7B6F766BC5Q46252211-CFA6F9CA-1B0F-45CD-AF16-889D2C20BF0DQ46865924-B1BB9524-3790-4D4B-89EA-D44DCFD0EE9DQ47120629-8E2852C8-C51A-4A54-89ED-08867DD53938Q47128718-1D5BBC16-CAEA-465D-97E4-A7998E0D37E5Q47131425-F8F6FAB2-C38F-4F5E-B3F5-6E6C969D683CQ47132242-EEB0089D-0EE8-4CFD-89AC-0CAC7222CF7CQ47138765-EFE708F1-F3BA-4438-BDDA-458566AA8CB2Q47154926-C0F3239E-A201-402C-9EB7-116B3466B79DQ47157402-4EB6ECE2-6CE8-44DB-8616-559484FC6015Q47225274-46DAF0CD-D501-466E-8E81-24D54D31B6F3Q47227422-4B6A63BF-4BE6-451D-A8B9-B7114A8BF2B4Q47301132-49796085-3211-4511-B0C1-04A8011C82C4Q47375181-E4D2A829-A7FC-43C3-8546-CCD406DA0A37Q47400647-2CE673AB-A689-4897-BE5F-70B23AF394F4Q47726847-8C453B65-2352-4FFD-B52D-7B7F55F639D0Q47735641-47BEBF38-16B5-4D62-AD85-BECECBFA3055Q47777833-5739D65C-FEF6-4DFB-9724-0A18C18390ADQ47781457-C1074237-B907-4C6F-940F-582EE5152814Q49333151-5B84F878-8AF7-4414-A563-AE3A33D74555Q49577605-FF02CD8C-1677-467E-89E3-FAD120854432Q49803828-2024B6EB-FBB3-45F2-8220-8E944681BDAFQ49971148-C07C0814-150A-4160-81FF-5F7F9FDA12C0Q50010320-289D91F7-18F6-4A29-91FB-F2420F8754A8Q50125923-A843E799-F5FA-4CAC-943E-5949314FBDFAQ50349181-286A9A37-0F99-49BD-8DCB-7C61082C893EQ51743770-BF709609-403A-4057-8DA6-9370AC83FDFFQ52587406-C7C8EE11-B6FA-4870-80CF-F4039EFE3F9AQ52611551-2650772B-07D3-4308-988B-31DC93D5326BQ52649470-5E615CB7-0A22-4C18-AE04-61D0F2DD0BAAQ52654643-842BD563-B6C7-4218-81D0-11A954DC6866Q52658584-5FC71489-5751-400D-AC21-15ED89D0A89DQ52689973-58504786-32A9-46C6-AE82-859841C2342AQ52707883-E36EB59F-DFBE-49C1-8897-CD748DA6E88EQ52714354-8779FE97-D564-44FB-840A-C4D8B0A488F6Q52720857-D2BC16A1-EB98-4EF7-B190-23498F74EEAFQ52801913-3264B0B8-47C2-4EEF-8C31-D84BDFD6E422Q53682041-C88F6587-A070-4236-B1DD-D59D5E55B25EQ54202082-3DC07AFB-C9EC-4948-BE71-FD61755EDA2CQ54215187-6A3326A6-DDAF-47D6-BB8E-B105767CF77C
P2860
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
@en
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
@nl
type
label
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
@en
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
@nl
prefLabel
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
@en
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
@nl
P2093
P2860
P50
P356
P1476
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
@en
P2093
Andrew Hill
C Lance Cowey
Celeste Lebbé
Christopher D Lao
Dana Walker
David Hogg
Dirk Schadendorf
F Stephen Hodi
James Larkin
Jean-Jacques Grob
P2860
P304
P356
10.1056/NEJMOA1709684
P407
P50
P577
2017-09-11T00:00:00Z